Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

Hims did not provide financial terms of the deal, but a company spokesperson said these details will be shared with its ...

Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that ...

Hims agreed to buy private European telehealth firm Zava, which operates in the U.K., Germany, France, and Ireland.

Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, experienced an 8% increase in its stock on Friday, May 30th, ...

Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

US telehealth group explores selling ‘compounded medications’ in new markets after buying London-based rival Zava ...

Investors are buying Hims & Hers Health ( HIMS 10.09%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they're selling off shares of ...

The direct-to-consumer telehealth company said the workforce reduction is unrelated to its weight-loss drug sector.

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.